Tag Archives: GWPH

Issue No.15 Sativa Magazine – April 2014

sativamagapril2014

Cannabis Investors and Marijuana Stocks Welcome to the Cannabis investment special. With listings of stocks for companies serving areas of the Cannabis market and lists of investors with money to burn. here is the launching pad for your Cannabis business idea. Work hard!

GW Pharmaceuticals to Present at the Piper Jaffray 25th Annual Health Care Conference

sativex-jpeg-resized-600

London, UK, 2 December 2013: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW’s Chief Executive Officer, is scheduled to present at the Piper Jaffray 25th Annual Health Care […]

GW Pharma rises on Swiss approval for Sativex

gw-logo

LONDON (ShareCast) – GW Pharmaceuticals (NasdaqGM:GWPH – news) has received regulatory approval in Switzerland for its treatment of spasticity due to multiple sclerosis (MS). A full marketing authorization has been granted by the Swissmedic authorities for Sativex in the treatment of moderate to severe spasticity in patients who have not responded adequately to other anti-spasticity medications. GW Pharma’s European […]

Scammers Target Cannabis Stocks

RiskAppetiteMunchies

Caught a segment on CNBC today about FINRA warning investors about the stocks within the Cannabis Industry. The following letter was issued by their Frauds & Scams Investor Alert: Marijuana Stock Scams With medical marijuana legal in almost 20 states, and recreational use of the drug recently legalized in two states, the cannabis business has been […]

GW Pharmaceuticals plc Opens an Investigational New Drug Application (IND) in the United States for a Sativex® Phase 3 Clinical Program as a Treatment for Spasticity Due to Multiple Sclerosis

gw_pharmaceuticals

LONDON, Aug. 14, 2013 /PRNewswire/ — GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW”) announced today that it has opened a Phase 3 Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to conduct a pivotal efficacy and safety clinical program to evaluate Sativex® for the treatment of spasticity due to […]

GW Pharmaceuticals to Present at the 33rd Annual Canaccord Genuity Growth Conference

gw_pharmaceuticals

LONDON, Aug. 8, 2013 /PRNewswire/ — GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW’s Chief Executive Officer, is scheduled to present at the 33rd Annual Canaccord Genuity Growth Conference on […]

GW Pharmaceuticals Announces Results of MS Spasticity Study Confirming Sativex Has No Long-Term Negative Effect on Cognition

gw-logo

LONDON, Aug. 5, 2013 /PRNewswire/ — GW Pharmaceuticals plc (NASDAQ: GWPH, AIM: GWP, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces top-line results from a 12 month placebo-controlled study of Sativex in patients with spasticity due to Multiple Sclerosis (MS). The […]

GW Pharmaceuticals plc Reports 2013 Third Quarter Financial Results

gw-logo

LONDON, Aug. 5, 2013 /PRNewswire/ — GW Pharmaceuticals plc (NASDAQ: GWPH, AIM: GWP, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces financial results for the third quarter ended 30 June 2013. RECENT OPERATIONAL HIGHLIGHTS Initial public offering on the […]

GW Pharmaceuticals Announces Pricing of Initial Public Offering on the NASDAQ Global Market

gw-logo

LONDON, May 1, 2013 /PRNewswire/ — GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW” or the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the pricing of its initial public offering of 3,500,000 American Depository Shares (“ADSs”) on the NASDAQ Global Market at […]